Clinical Trials & Research

After several decades of improvement, inequality in infant health is once again on the rise in the United States, a pair of Brown University researchers has found. Between 1989 and 2010, the health gap between infants born to the most socially advantaged mothers — those who are married, highly educated and white — and infants

CAMBRIDGE, Mass.–(BUSINESS WIRE) December 5, 2020 — Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new clinical data from its Phase 2 trial evaluating SY-1425, its first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with azacitidine in two acute myeloid leukemia (AML) patient

By Dan Hutchins, M.PhilDec 6 2020 A team of researchers – from Yale University, Wayne State University, the University of Michigan Medical School, the Michigan Department of Health and Human Services, and the University of Maryland School of Medicine – have explored how the coronavirus disease 2019 (COVID-19) pandemic has disproportionately affected Black Americans. They

NEW YORK & MAINZ, Germany–(BUSINESS WIRE) December 02, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2), against COVID-19. This constitutes the first Emergency Use

Researchers in the US have re-analyzed the data on herd immunity from spring 2020 from Europe. Their study shows that the herd immunity threshold is much higher than earlier speculated. The team – from the University of Texas at Austin and The Santa Fe Institute, New Mexico – have released at the preprint server medRxiv*.

NEW YORK–(BUSINESS WIRE) November 23, 2020 — Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 BASIS study of marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (anti-TFPI) being evaluated for the treatment of people with severe hemophilia A or B, with or without inhibitors. BASIS is a

The coronavirus 2019 (COVID-19) pandemic has interrupted social and economic activity and has led to a huge wave of sickness and death. However, there are other healthcare costs as well, one of which is the interruption of scheduled screening for diseases that can be cured if diagnosed early; one such disease is cervical cancer. A

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 30, 2020– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis.

A research team has reviewed the existing literature on compounds derived from molluscs used for treating respiratory diseases. This may provide clues for developing new drugs along with incorporating traditional medicines. Respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) are among the leading causes of death and disability worldwide. The respiratory system,

The efficacy of the Sputnik V vaccine is 91.4%, based on the second interim analysis of data obtained 28 days after administering the first dose (7 days after the second dose). Calculation was based on the analysis of data on volunteers (n = 18,794) who received both the first and second doses of the Sputnik

We’ve all been there. Whether we’re stuck in traffic at the end of a long day, or eagerly anticipating the release of a new book, film or album, there are times when we need to be patient. Learning to suppress the impulse for instant gratification is often vital for future success, but how patience is

November 25, 2020 — Under FDA law, approval of a new drug requires substantial evidence of effectiveness and a demonstration of safety for the drug’s intended use(s).  The approval of remdesivir (Veklury) for the treatment of patients hospitalized with COVID-19 met this legal and scientific standard. BackgroundRandomized, controlled trials are the gold standard for evaluating

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen, is a novel disease that scientists are racing to better understand. This has been in the hope of developing therapeutic and prophylactic approaches to help save lives and curb the virus’s spread. A team of researchers at the Robert

23 November 2020  Two different dosing regimens demonstrated efficacy with one showing a better profile No hospitalisations or severe cases of COVID-19 in participants treated with AZD1222  Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary

Reviewed by Emily Henderson, B.Sc.Nov 24 2020 Funding from the National Institutes of Health will enable a Penn State researcher to study whether vitamin D supplementation could help people ward off or reduce symptoms caused by COVID-19. Margherita Cantorna, distinguished professor of molecular immunology and nutrition in the College of Agricultural Sciences, received nearly $241,000

KENILWORTH, N.J.–(BUSINESS WIRE) November 16, 2020 — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a collaboration with the Bill & Melinda Gates Foundation (the foundation) where the foundation is committing to provide funding to support a pivotal Phase 3 study investigating a once-monthly oral pre-exposure prophylaxis (PrEP)1

Reviewed by Emily Henderson, B.Sc.Nov 20 2020 It isn’t a death sentence if a COVID-19 patient suffers a cardiac arrest while getting treatment for the virus in the hospital, according to new research that contradicts reports from early on in the pandemic. The new insight from a researcher in the Perelman School of Medicine at

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 16, 2020– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met

A recent study conducted by a team of international scientists has revealed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19), suppresses the expression and function of human angiotensin-converting enzyme 2 (ACE2) and induces the expression of interferon-stimulated genes at the initial phase of infection. The study is

Wednesday, November 18, 2020 Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group Efficacy was consistent across age, gender, race and ethnicity demographics; observed efficacy in adults

Vitamin D has gained immense popularity amid the coronavirus disease 2019 (COVID-19) pandemic. Several studies have tied vitamin D deficiency to coronavirus infection. Health experts are investigating if taking vitamin D may help protect against severe COVID-19. A team of researchers at the University of São Paulo in Brazil aimed to determine if vitamin D3

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. 15, 2020. This interim review of the data suggests that the vaccine is safe and

Reviewed by Emily Henderson, B.Sc.Nov 16 2020 The fish oil-based medication known as omega-3 carboxylic acids or omega-3 CA did not decrease the risk of cardiac events compared to a placebo, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2020. The virtual meeting is Friday, November 13-Tuesday, November 17, 2020,

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 11, 2020– Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has completed case accrual for the first interim analysis of the Phase 3 COVE study of mRNA-1273, its COVID-19 vaccine candidate. Moderna has seen

Nov 13 2020 Porvair Sciences reports, due to promising results, it has agreed with its collaborative partners to make additional investment in the CEAT project** which aims to dramatically improve the diagnosis and treatment of ovarian cancer. In the initial stage of the CEAT (Cluster for Epigenomic and Antibody Drug Conjugate Therapeutics) project – Porvair

12 November 2020 — The CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalised with respiratory symptoms of COVID-19 did not meet the primary efficacy endpoint. The addition of Calquence to best supportive care (BSC) did not increase the proportion of patients who remained alive and free of respiratory failure. No new safety signal for Calquence was observed in the

Nov 12 2020 Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced a new partnership with LabVoice to provide R&D scientists with the ability to record, access, and track data within an electronic laboratory notebook (ELN) using hands-free

Daix (France), November 10, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced conclusions from its end-of-phase II meeting with the U.S. Food and Drug